Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving AR Blockade and AR Blockade + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to AR blockade that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Clinical Trial Recruitment Navigator
- 電話番号:310-423-5842
- メール:GroupCancerTrialInformation@cshs.org
研究連絡先のバックアップ
- 名前:Edwin Posadas, MD FACP
- メール:edwin.posadas@csmc.edu
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope
-
コンタクト:
- Tanya Dorff, MD
- 電話番号:626-256-4673
- メール:tdorff@coh.org
-
Los Angeles、California、アメリカ、90048
- 募集
- Cedars-Sinai Medical Center
-
副調査官:
- David Hoffman, MD
-
副調査官:
- Robert Figlin, MD FACP
-
副調査官:
- Kevin Scher, MD MBA
-
副調査官:
- Leland Green, MD
-
副調査官:
- Kristopher Wentzel, MD
-
副調査官:
- Jun Gong, MD
-
コンタクト:
- Clinical Trial Recruitment Navigator
- 電話番号:310-423-5842
- メール:GroupCancerTrialInformation@cshs.org
-
コンタクト:
- Edwin Posadas
- メール:edwin.posadas@csmc.edu
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute and Hospital
-
コンタクト:
- Umang Swami, MD
- 電話番号:801-587-4381
- メール:Umang.Swami@hci.utah.edu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
History of castration-resistant prostate cancer with rising PSA on a contemporary ARSI (e.g. abiraterone or, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs.
- PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on an ARSI
- Patient must be surgically castrated or have serum testosterone concentrations much be consistent with castrate levels of testosterone (under 50 ng/dL) while on LHRH analog therapy
- Patient must have had 1 and can have up to 2 prior AR targeted agents (if patients have had previous enzalutamide, they will be considered only for arm C). therapy with the exception of apalutamide.
- Patients may not have had previous chemotherapy with the exception of docetaxel administered for castration-sensitive disease.
-
Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.
-
Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
-
Resolution of adverse events results as described below:
- If the subject's patient's most recent line of therapy is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or less
- If the subject's patient's most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or less, with the exception of fatigue, alopecia and neuropathy (which must resolve to CTCAE grade 2)
-
Adequate organ function
-
All patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide/enzalutamide and/or carotuximab)
-
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
Exclusion Criteria:
- Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
- Other prior malignancy requiring active anticancer therapy
- Prior exposure to carotuximab or any CD105 targeted antibody
- Any major surgical procedure, in the opinion of the treating physician, within 2 weeks of starting therapy
- Uncontrolled chronic hypertension defined as sustained systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy
- Active bleeding or pathologic medical conditions, including but not limited to factor deficiencies, hemophilia, etc., that carries a high bleeding risk
- Use of thrombolytics within 10 days prior to the first day of carotuximab
- Known hypersensitivity to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
- A known diagnosis of Osler-Weber-Rendu syndrome
- Ascites or pericardial or pleural effusion requiring external drainage procedures
- History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset of weakness or numbness that cannot be explained by other medical history.
- Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infarction, NYHA Class II or worse congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG.
- Deep venous thrombosis within the past 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred but clearance should be given by the local PI.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:Enzalutamide Naive - Monotherapy
After progression, subjects will crossover to combination therapy |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
他の名前:
|
|
実験的:Enzalutamide Naive - Combination therapy (Androgen Receptor Blockade + Carotuximab)
Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
他の名前:
Carotuximab administered intravenously at the following doses: Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose. |
|
実験的:Enzalutamide Exposed - Combination therapy (Androgen Receptor Blockade + Carotuximab)
Androgen Receptor is Apalutamide 240mg for Lead-In group & Enzalutamide 160mg for all other groups |
Standard of care Apalutamide 240 mg / Enzalutamide 160mg administered orally and daily on Days 1-28 of every 28 day cycle
他の名前:
Carotuximab administered intravenously at the following doses: Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression free survival (rPFS) between patients receiving AR blockade and AR blockade + carotuximab
時間枠:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Adverse events (grade 3 or higher) related to carotuximab and AR blockade
時間枠:From start of study treatment through 4 weeks on treatment
|
Grade 3 or above treatment related adverse events as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
From start of study treatment through 4 weeks on treatment
|
|
Overall radiographic response rate (ORR) of the combination of AR blockade + carotuximab
時間枠:From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Participants of the combination of AR blockade + carotuximab, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3 |
From the start of combination study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
Proportion of patients resistant to AR blockade benefit from the addition of carotuximab
時間枠:From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Participants of the monotherapy group that crossover to combination therapy at progression, with confirmed complete response (CR) or partial response (PR) per RECIST v.1.1 and Prostate Cancer Working Group 3 |
From the start of combination therapy study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
Overall radiographic response rate (ORR) in the overall population
時間枠:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
Determined by confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3 |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
To determine the radiographic progression free survival (rPFS) in the overall population
時間枠:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
|
To determine the biochemical PFS (by PCWG3) in the overall population
時間枠:From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
From the start of study treatment until documented progression, per Prostate Cancer Working Group 3, or death due to any cause. |
From the start of study treatment until documented progression, or death due to any cause, up to 30 days of follow-up after end of treatment.
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Edwin Posadas, MD FACP、Cedars-Sinai Medical Center
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IIT2021-06-Posadas-AR105
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。